To substantiate in vivo our in vitro results above, we determined plasma HE4 levels in 10 randomly selected CF individuals homozygous for p. Phe508del-CFTR mutation who were under Orkambi® (LUM/IVA) medication. Here, WFDC2 is linked to cystic fibrosis.